NYSE:EW - Edwards Lifesciences Stock Price, Forecast & News

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences's stock split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly issued shares were issued to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences Corp (NYSE:EW) released its quarterly earnings results on Wednesday, October, 23rd. The medical research company reported $1.41 EPS for the quarter, topping the Zacks' consensus estimate of $1.22 by $0.19. The medical research company had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.04 billion. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The firm's revenue was up 20.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.07 earnings per share. View Edwards Lifesciences' Earnings History.

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Edwards Lifesciences.

Edwards Lifesciences will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Edwards Lifesciences updated its FY20 earnings guidance on Thursday, December, 5th. The company provided earnings per share (EPS) guidance of $6.05-6.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.98. The company issued revenue guidance of $4.5-5.0 billion, compared to the consensus revenue estimate of $4.70 billion.

19 analysts have issued 1-year price targets for Edwards Lifesciences' stock. Their forecasts range from $159.00 to $285.00. On average, they anticipate Edwards Lifesciences' stock price to reach $239.83 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View Analyst Price Targets for Edwards Lifesciences.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.

News coverage about EW stock has trended somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Edwards Lifesciences earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Edwards Lifesciences.

Edwards Lifesciences saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,350,000 shares, an increase of 18.7% from the December 15th total of 1,980,000 shares. Based on an average trading volume of 1,180,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.1% of the shares of the stock are sold short. View Edwards Lifesciences' Current Options Chain.

Some companies that are related to Edwards Lifesciences include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Home Depot (HD), Visa (V), Walt Disney (DIS), Mastercard (MA), UnitedHealth Group (UNH), QUALCOMM (QCOM) and CVS Health (CVS).

Edwards Lifesciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Huntington National Bank (0.15%), Chicago Capital LLC (0.07%), Birch Hill Investment Advisors LLC (0.07%), Scout Investments Inc. (0.06%), Nisa Investment Advisors LLC (0.06%) and Commerzbank Aktiengesellschaft FI (0.05%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Country Trust Bank, Gateway Investment Advisers LLC, Tributary Capital Management LLC, Assenagon Asset Management S.A., OLD National Bancorp IN, Meag Munich Ergo Kapitalanlagegesellschaft MBH and Birch Hill Investment Advisors LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

EW stock was acquired by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Scout Investments Inc., Commerzbank Aktiengesellschaft FI, Tuttle Tactical Management, Huntington National Bank, TrimTabs Asset Management LLC, Nisa Investment Advisors LLC and Diversified Trust Co. View Insider Buying and Selling for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EW stock can currently be purchased for approximately $238.64.

Edwards Lifesciences has a market capitalization of $49.77 billion and generates $3.72 billion in revenue each year. The medical research company earns $722.20 million in net income (profit) each year or $4.70 on an earnings per share basis. Edwards Lifesciences employs 12,800 workers across the globe.View Additional Information About Edwards Lifesciences.

The official website for Edwards Lifesciences is http://www.edwards.com/.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]